$bxrx and $grom had offerings and are up nicely today.

$TGTX FDA approval for Billion dollar MS drug — great things in store 2023 $DRMA just officially dropped offering, makes me feel company has something good up it’s sleeve.

Probably get a bonus this year for all the fine work she's done with reverse splits and offerings.

Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.

$TGTX makes a lot of sense to do a 300M offering here imo

What stuck out was the combined value proposition: efficacy, safety, convenience, marketability, pricing, etc.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

$TGTX FDA approval for Billion dollar MS drug — great things in store 2023 $DRMA just officially dropped offering, makes me feel company has something good up it’s sleeve.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

Amazing positive news from the TGTX 20221229 conference call, FDA approved, 🚨🔥🚨 Ublituximab Briumvi: 1) No need for additional funds, no offering, no need for capital raise, because 220 million in cash reserves expected to last until mid 2024.

Their management is setting up a good offering price, which is alright

The pricing, the safety, the ease of usage (pill and no MRI's) and the efficacy/performance.

Add to that their ca$h position and the likelihood of a offering in the next few days makes this an easy short.

It is the perfect timing set to have the attention of Wall Street and to be in the spotlights the whole week long, offering free champagne to everyone at CTAD.